T 1179/23 (Compositions of dabigatran etexilate / TOWA PHARMACEUTICAL) du 14.01.2026
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2026:T117923.20260114
- Date de la décision
- 14 janvier 2026
- Numéro de l'affaire
- T 1179/23
- Requête en révision de
- -
- Numéro de la demande
- 13704974.8
- Langue de la procédure
- Anglais
- Distribution
- Non distribuées (D)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN ETEXILATE
- Nom du demandeur
- TOWA PHARMACEUTICAL EUROPE, S.L.
- Nom de l'opposant
- Aera A/S
Hamm&Wittkopp Patentanwälte PartmbB - Chambre
- 3.3.07
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 123(2)European Patent Convention Art 56European Patent Convention R 139Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 012(6)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Mots-clés
- Late-filed evidence - admittance in appeal proceedings (yes)
Requests filed during appeal proceedings - admitted (yes)
Request for continuation in writing - rejected
Validity of priority date (yes)
Amendments - correction of obvious errors (no)
Inventive step - main request and auxiliary requests 1 and 2 (no), auxiliary requests 3 and 15 (yes) - Exergue
- -
- Affaires citantes
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside.
The case is remitted to the opposition division with the order to maintain the patent in amended form on the basis of claims 1 to 6 of auxiliary request 3 filed with the reply to the appeals, paragraph [0088] of the description filed with the reply to the appeals, and the further paragraphs of the description to be adapted.